Today the German-American biotechnology company MediGene AG (Frankfurt, TecDAX) announced preliminary financial results for 2005: revenues increased from 13.1 million € to 19.7 million € due to an increase in sales of MediGene's first drug on the market*, and the conclusion of a license agreement with Glaxo Group Ltd.
